Ann: 44Medical unveils VQ product at premier US lung conference, page-24

from Todays $tockhead !?!
4DMedical says its CT technology is a breakthrough

4DMedical (ASX:4DX) has announced a significant technological breakthrough and milestone in its product development strategy.
The company said its CT-based ventilation-perfusion product has now progressed to a developmental stage, which will allow the company to release early clinical data.
This clinical data was presented at the annual conference of the American Thoracic Society in Washington DC yesterday.
The CT:VQ technology enables quantitative perfusion data and visualisations to be extracted from non-contrast paired inspiratory-expiratory CT scans.
It achieves this by measuring the regional motion of lung tissue, while also assessing local density changes to quantify regional blood-mass change.
Through this technology, hospitals can avoid the significant capital expenditure involved in mitigating radiation risks of operating a Nuclear Medicine VQ scanner.
4D Medical CEO and founder Dr Andreas Fouras said that in a matter of years, the company’s XV Technology has set the scene for a step-change in respiratory imaging, disrupting methods that in some cases have been in use for over a century.
“Our progress with CT:VQ keeps us on track for submission to the FDA in calendar 2023, and with an average turn-around time from the FDA, we expect to be in the US market around the middle of calendar 2024,” Fouras said.